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Summary.-The immunotherapeutic value of tumour extracts or B.C.G. in prevent-
ing either the occurrence of primary tumours or the recurrence of tumours in
surgically resected animals has been examined. A transplantable methylcholan-
threne induced tumour in DBA/2J mice was used. Neither tumour extract nor
chemically modified extract was effective in preventing tumour growth in immunized
animals, even though the mice demonstrated measurable levels of cell mediated
tumour immunity at the time of tumour challenge. The frequency of tumour
recurrence after resection of small tumours (about 1-0 g) was significantly lowered
by treatment of the mice with a combination of B.C.G. and either modified or un-
modified tumour extract. The frequency of recurrence after resection of large
tumours (about 2-5 g) was not affected by any form of immunotherapy although the
survival time of treated animals was significantly prolonged. The immunological
status of animals with small and large tumours was examined and it was shown
that mice with 1-0 g tumours have unimpaired mitogen responsiveness and measur-
able tumour specific immunity, whereas mice bearing large tumours (2.5 g) have a
markedly impaired immune system.
IMMUNIZATION ofexperimental animals
against challenge with tumour inducing
doses of tumour cells has had varied
success in a number of tumour systems.
It has been generally observed that the
greatest success with this type of protocol
has involved the use of tumour cells,
killed or inactivated with agents such as
irradiation or mitomycin C (Alexander,
Connell and Mikulska, 1966; Lin, Huber
and Murphy, 1969; Revesz, 1960; Bald-
win, Embleton and Moore, 1973). In
general, attempts to immunize animals
against tumour cell challenge with ex-
tracts from tumour cells have been
unsuccessful, even when such extracts
have been shown to contain tumour
specific transplantation antigens (Baldwin
et al., 1973).
Recently, the use of nonspecific im-
munostimulants such as B.C.G., either
20
alone or in combination with inactivated
tumour cells, as a method of treatment
of established tumours has aroused con-
siderable interest. Several studies have
demonstrated regression of established
tumours by administration of B.C.G.
alone to guinea-pigs (Zbar et al., 1972;
Zbar and Tanaka, 1971) or B.C.G. in
combination with autochthonous tumour
cells treated with neuraminidase and
mitomycin C to mice (Simmons and
Rios, 1971). However, another study
has shown that while B.C.G. treatment at
the time of grafting of a polyoma tumour
in rats prevented tumour take, similar
treatment of established tumours, or
tumours which had been incompletely
excised, caused enhanced tumour growth
(Bansal and Sjogren, 1973).
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growth is obviously complex, and may
apparently be either beneficial or detri-
mental depending on a number of
variables. In particular, the relative
effects of circulating antibody versus
sensitized cells on tumour growth remain
to be clarified. However, Rouse, Rolling-
hoff and Warner (1973) have shown that
thymus-derived (T) cells from tumour
immune mice were responsible for the
adoptive transfer of immunity to tumour
cell challenge in syngeneic mice. Conse-
quently, many of the efforts in immuno-
therapy are being addressed towards
procedures which may selectively en-
hance a cell mediated immune response
to tumour cells, as opposed to a humoral
response.
It has been observed by some workers
that chemical modification of some soluble
antigens abrogates their ability to evoke
immediate (or antibody mediated) allergic
responses in animals sensitized to the
unmodified antigens, while the delayed
(or cell mediated) response remains un-
changed (Parish, 1971a, b; Shirrmacher
and Wigzell, 1972; Thompson et al.,
1972). It is possible that immuniza-
tion of animals with material derived
from tumour cells, and modified in such
a way that only T cells would be
capable of responding to both it and
the unmodified material, would make
it possibe to observe the effect of a
strictly cell mediated response to tum-
our antigens in the absence of a B cell
response.
The work reported here involves a
study of the ability of extracts from
tumour cells, both unmodified and modi-
fied by acetoacetylation, to protect
DBA/2J mice against challenge with
known tumour inducing doses of a tumour
cell line derived from a methylchol-
anthrene induced tumour. The immuno-
therapeutic value of these preparations,
administered either by themselves or in
combination with B.C.G., in preventing
recurrence of tumours after resection of
either small or large tumours has also
been studied.
MATERIALS AND METHODS
Mice.-DBA/2J female mice were ob-
tained from Jackson Laboratories, Bar
Harbor, Maine and were used when they
reached 20 g.
Tumour.-A methylcholanthrene induced
rhabdomyosarcoma carried in DBA/2J mice
was used. All mice developed tumours
when they were injected with 104 or more
cells. No spontaneous regressions have been
observed and all mice withuntreated tumours
die within 8 weeks. Tumour cells were
cultured in vitro in RPMI-1640 medium
supplemented with 10% heat inactivated
(56°C, 30 min) foetal calf serum, penicillin
(100 i.u./ml), streptomycin (100 jug/ml) and
Fungizone (amphotericin B sodium desoxy-
cholate 25 ysg/ml).
Tumour extracts. Large tumours weigh-
ing between 4-0 and 5 0 g were removed
from mice and were minced first with
scissors and then with a tissue grinder.
Soluble antigens were extracted by stirring
the minced tumour tissue in twice its volume
of 3 0 mol/l KCI overnight at 4°C. Extracts
were centrifuged at 25,000 g for 1 h and the
supernatant was dialysed at 4°C overnight
against 100 vol. 0.85% saline. The material
was again centrifuged as above and sterilized
by filtration through a 0 45 ,um millipore
filter. Protein estimations of the filtrate
were made by the Lowry method.
Acetoacetylation.-Tumour extracts were
acetoacetylated according to the procedure
followed by Parish (1971a). That the modi-
fied extract no longer cross-reacted with
unmodified extract at the humoral level, but
continued to cross-react at the cell mediated
level was established by immunizing guinea-
pigs with the native tumour extract and
subsequently skin testing them with both
native and modified extracts. Guinea-pigs
were immunized with 3-0 mg of tumour
extract injected intramuscularly in a total
volume of 0-3 ml of 50% complete Freund's
adjuvant (CFA). Ten days later their
flanks were shaved and they were skin
tested with 50-0 ,ug of both unmodified and
modified extract in a total of 01l ml saline.
All the guinea-pigs so tested gave classic
immediate and delayed skin reactions to the
unmodified extract but only delayed re-
sponses to the acetoacetylated preparations.
Immunization.-Mice were immunized to
either the tumour extract or its aceto-
acetylated derivative by 6 subcutaneous
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injections containing 50-0 Hg of protein in
50% v/v CFA in 0-2 ml at weekly intervals.
Control mice were injected with 0-2 ml of
50% CFA in saline. Following immuniza-
tion, the animals were challenged with
either 104 or 105 viable tumour cells, and
were examined twice a week for the presence
and the rate of growth of tumours. Non-
immunized (normal) mice were controls
throughout.
In some experiments it was essential to
obtain control mice which were immune to
tumour cell challenge. These immune mice
were obtained by inducing tumours with a
cell inoculum and resecting them. Those
mice not developing tumour recurrences
were invariably resistant to challenge with
105 tumour cells, and these animals were used
as immune controls.
Tumour resection and immunotherapy.-
Mice were immunized with a single sub-
cutaneous injection of 50 0 ,ug of PPD
(Connaught Medical Laboratories, Toronto,
Ontario) in 50% v/v CFA (Difco Labora-
tories, Detroit, Michigan) in a total volume
of 0-2 ml. Two weeks later all animals
were injected subcutaneously in the right
abdominal side with 105 tumour cells, a
dose which produces 100% takes within
7-12 days.
This study involved, in part, an evalua-
tion of post-surgical immunotherapy at
different stages of tumour growth. Two
main experiments were carried out, the only
variable being the size of tumour at time
of resection, so that in the 2 experiments
tumours were removed when they had
reached either about 1-0 g or 2-5 g. Mice
were partially anaesthetized with Nembutal
(pentobarbitone sodium) andwere maintained
under ether anaesthesia during surgical
removal of the tumours. Before surgery
the animals were randomized and divided
into the desired number ofgroups. Immedi-
ately after surgery, and at weekly intervals
thereafter, the mice were treated in one of
the following ways: Group A, 0-2 ml of
PBS (0.01 mol/l phosphate buffered saline
pH 7.5); Group B, 1-0 mg of B.C.G. (Con-
naught Medical Laboratories, Toronto, On-
tario) in 0-2 ml of PBS; Group C, 1-0 mg
of B.C.G. plus 50-0 ug of tumour extract in
0-2 ml of PBS; Group D, 1-0 mg of B.C.G.
plus 50-0 ,ug of modified tumour extract in
0-2 ml of PBS; Group E, 50-0 ,ug of tumour
extract in 0-2 ml of PBS; Group F, 50-0 Htg
of modified tumour extract in 0-2 ml of
PBS.
The B.C.G. (viable freeze dried organisms)
was made up in PBS immediately before
use. The appropriate injections were given
subcutaneously in the abdomen. The ani-
mals were maintained on antibiotics (terra-
mycin, animal formula, Pfizer) after surgery.
The mice were observed for 7 weeks after
surgery and the time of tumour recurrence
and the time of death following recurrence
were noted.
Assessment of cell mediated immunity.-
Tumour specific cell mediated immunity
was measured by the colony inhibition
technique developed by Hellstrom and Hell-
strom (1971). These tests were carried out
on immunized animals at several stages
during tumour growth, 5 days after resection
and on animals which did not develop
tumourrecurrences afterresection. Cultured
tumour cells were harvested from 100 x 20
mm petri plates by trypsinization (2-0 ml of
0-25% typsin for 10 min at 37°C). Foetal
calf serum was added to stop enzyme action
and the cells were washed once by centrifuga-
tion in PBS. The cells were counted and
made up to a concentration of 200 cells/ml
in RPMI-1640 + 10° heat inactivated foetal
calf serum. Then 1-5 ml of the suspension
was dispensed to a number of 60 x 15 mm
plastic Falcon petri plates and incubated
overnight to allow cell attachment. The
following morning the medium was removed
and 5 x 106 spleen cells from test animals
in 1-5 ml of RPMI-1640 without serum
were added to each plate. The following
day an additional 1-5 ml of medium con-
taining 20% FCS was added to each plate.
The plates were incubated for 7-8 days
from the time of addition of the spleen cells,
after which time the medium was removed
and each plate was rinsed 3 times with
saline. Colonies were stained for 30 min
with 1-5 ml of crystal violet (1 g/100 ml of
methanol). Excess stain was washed off
with tap water and the plates were dried,
after which macroscopical enumeration of
colonies was carried out.
Mitogen stimulation.-The ability of
mouse spleen cells to respond to the mitogens
concanavalin A (ConA) and bacterial lipo-
polysaccharide (LPS) was assessed at various
times, using a microtitre culturing pro-
cedure which has been described fully
elsewhere (Whitney, Levy and Smith, 1974).
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Statistical analyses.-Where appropriate,
results are expressed as the mean value plus
or minus the standard error of the mean.
The statistical significance of differences in
mean values was determined by Student's
t-test. The x2 test was used to evaluate
differences in the tumour recurrence fre-
quency in various test groups. Differences
were taken to be significant ifthe probability
that the observed difference occurred by
chance was less than 5% (i.e., P < 0 05).
RESULTS
Immunization to tumour challenge
Mice which were immunized with
either tumour extract or modified tumour
extract before tumour cell challenge with
either 104 or 105 viable cells showed no
significant differences in tumour growth
rate from control mice immunized with
CFA only. Experimental groups of 10
animals were used and the tumour growth
curves for 104 and 105 cell challenges are
shown in the Fig. Even though the
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FiG.-Rate of tumour growth in control
mice injected with either 105 (0 - -0) or
104 (A---A) tumour cells and in mice
previously immunized with modified
tumour extract (0- -0; 105 cells;
A----, 104 cells).
immunized mice were not protected
against tumour challenge, they exhibited
significant cell mediated immunity specific
for the tumour cells, as measured by
colony inhibition (Table I). Results from
animals immunized with unmodified tu-
mour extract (not shown) were essentially
the same as those shown for modified
extracts in the Fig. and Table I.
TABLE I.-Results of Colony Inhibition
Tests Run on Spleen Cells taken from
either Non-immune Mice or from Mice
Immunized with Modified Tumour Ex-
tract
Spleen cell
source
Non-immune
(pooled cells run
in octuplicate)
Immunized animals
-1
-2
-3
4
Colonies %
per plate Inhibi-
±s.e. mean tion p
514±3 -0
37 0±5.4
13 -0A0*31
38-5±0-65
31 *2±0-18
28
75
25
39
<0 05
<0-001
<0 05
<0 005
-5 43-0±1-30 16 <0 05
Immunotherapy experiments
The effects of the various types of
immunotherapy on mice from which
tumours had been resected when they
reached approximately 1.0 g are sum-
marized in Table II. It can be seen that
while B.C.G. alone did not significantly
reduce the frequency oftumour recurrence
compared with untreated controls, the
combined therapy using B.C.G. with
either unmodified or modified tumour
extracts (Groups C and D) did. Neither
of the tumour extracts on their own
reduced the frequency of tumour recur-
rence significantly, nor in any instance
was the survival time increased as a
- result of immunotherapy. It was clear
50 that in these animals, combined specific
and nonspecific immunostimulation pro-
duced the most beneficial effect.
The results obtained from a similar
experiment, in which tumour sizes were
about 2-5 g at the time of resection are
summarized in Table III. It can be
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TABLE II.-The Incidence of Tumour Recurrence in Control and Immunotherapeutically
Treated Mice after Primary Tumour Resection
Time of Time of death:
Average No. of recurrence after resection
Experimental tumour size recur- (days±s.e. (days±s.e. group ±s.e. mean rences % P* mean) Pt mean) Pt
A-Control 0-95+0-05 16/37 43 14-2±0-8 28-0±1-4
B-B.C.G. 0-96±0-06 10/32 31 >0-2 16-3±1-4 NS 29-0±2-2 NS C-B.C.G.+tumour 0-72+0-05 3/21 14 <0 05 11-7±0-5 NS 23-3±0-5 NS extract
D-B.C.G.+modified 0 96±0 05 5/33 15 < 0 05
tumour extract
E-tumour extract 0-79±0-07 7/19 37 >0-5
F-modified tumour 0-97±0-05 8/32 25 <0-2
extract
10-2±0-5 NS 23-3±1-2 NS
20-7±1-8 <0-02 34-9±3-2 NS
17-0±1-1 NS 29-8±1-1 NS
* Analyses based on chi square test.
t Analyses based on Student's t test.
t Data compiled on mice developing recurrences.
TABLE III.-The Incidence ofTumour Recurrence in Control and Immunotherapeutically
Treated Mice after Primary Tumour Resection
Average No. of
Experimental tumour size recur-
group ±s.e. mean rences %*
A-Control 2-60±0-07 20/27 74
B-B.C.G. 2-51±0-07 18/25 72
D-B.C.G.+modified 2-53±0-08 27/30 90
tumour extract
F-Modified tumour 2-66±0-10 17/28 61
extract
Time of
recurrence
(days±s.e.
mean)
12-2±0- 7
14-3±1-4
13-6±1-0
Pt
NS
NS
Time ofdeath:
after resection
(days± s.e.
mean)
23-8±1-2
31-3±2-1
32-5±1-6
Pt
<0- 005
< O *0005
14-4±1-0 <0-2 29-1±1-4 <0-01
* On the basis of chi square analyses none of the treated groups differed significantly from the controls.
t Analyses based on Student's t test.
: Data compiled only on mice developing recurrences.
seen that immunotherapy had a rather
different effect in these animals. The
recurrence frequency in all of the treated
groups was not significantly different
from that of the controls. However, the
mean survival times of all the animals on
immunotherapy were significantly longer
than the mean survival time of control
animals. In both experiments, all mice
not developing recurrences after 4 weeks
were found to be resistant to challenge
with 105 tumour cells.
Immune status of tumour bearing animals
It was felt that the different effects
of immunotherapy seen in the 2 groups
of mice might be related to the immuno-
logical status of animals at the time of
tumour resection. Consequently repre-
sentative mice with tumours of approxi-
mately 1-0 g and 2-5 g were examined
with respect to their immunological com-
petence before surgery and 5 days follow-
ing tumour resection. Test animals were
sacrificed and their spleen cells tested for
mitogen response to both ConA and LPS
as well as for specific cell mediated im-
munity by the colony inhibition test.
In each case the responses of test mice
were measured in comparison with normal
non-immune mice. The results are shown
in Tables IV, V and VI. As can be seen
(Table IV) the mitogen responses in
animals with the smaller tumours were
not significantly lower than those of non-
immune controls. However, mice bearing
larger tumours had no response to either
ConA or LPS at the time of resection,
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TABLE IV. Mitogen Responses in the Spleen Cells of Mice with Tumours of about 1P0
or 2-5 g and 5 Days after Tumour Resection. Stimulation Indices are Measurements
of Increased Uptake of 3H-thymidine in Mitogen Treated Cultures Compared with
ct/min in Untreated Control Cultures
Spleen cell source
(5 animals per group)
Non-immune
Tumour bearers (1 -0 g)
Tumour resectect (1 0 g)
Tumour bearers (2-5 g)
Tumour resected (2 - 5 g)
Background(I
ct/min+s.e,. mean
(uinstimulated culttures)
6090± 1529
5560± 1042
7000±2245
6380±338
9690±1212
ConA± s.e.
mean
34-4±8-1
26-1±2-6
29-6±10-1
0 91+0-25
12-5±1- 9
Stimulation indices
,- A~~~~~~
>0- 3
>0- 5
<0-01
<0-05
* Statistical differences between test groups and non-immune controls were measured by the Student's
t test.
TABLE V.-C"olony Inhibition by the Spleen
Cells of Mice with Tumours of about
IG0 g and 5 Days after Tumour Resection
Spleen cell No. of colonies 0%
source ± s.e. mean Inhibition P
Non-immune 105 -0±4-0
tumour bearers 83-2±1-4 21 <0-01
95-8+3-5 9 NS
86 0±+2-9 18 < 0 05
86-3±1-5 18 <0-05
87-8±2-9 16 <0-05
74-2±2-7 29 <0-01
Non-immune 29-0±1-0
resections 20-5±2-5 29 <0-01
22-0-1 3-0 24 <0-05
23-0±2-0 21 <0-05
22-7±1-8 22 <0-05
TABLE VTI. Colony Inhibition by the
Spleen Cells of Mice with Tumours of
about 2-5 g, and 5 Days after Tumour
Resection
Spleen cell No. of colonies
±s.e. mean
97-4± 3-0
99-5± 1-A
95-2+4-0
60-0 0 5-4
104-2 4-9
91-5±5-6
75-0± 4-7
79-5 ±4-4
83-2 ± 7-0
90-8 2-1
91-5 +4-3
source
Non-immune
tumour bearers
Tumour resections
0/
,0
Inhibi-
tion
2
38
6
23
18
15
7
6
NS
NS
<0- 001
NS
NS
<0-01
<0-01
NS
NS
NS
and while some recovery (particularly of
the ConA response) of responsiveness was
apparent 5 days after resection levels to
both mitogens were significantly below
those ofthe controls. Backgroi-u:d counts
in unstimulated cultures usually were
between 5 x 103 and 104 ct/min and
did not differ significantly between experi-
mental groups, so that stimulation indices
are a true reflection of total counts in
the cultures.
The results of colony inhibition tests,
using spleen cells from animals with
1P0 g tumours before and 5 days after
surgery are shown in Table V. Signifi-
cant inhibition was observed in 5 of the
6 tumour bearers and in all ofthe resected
animals. These observations imply that
at the early stages of tumour growth, the
mice maintained normal levels of lympho-
cyte competence and demonstrate specific
tumour immunity. In contrast to this
observation, only one mouse out of 5
bearing large tumours demonstrated tu-
mour specific immunity (Table VI). Al-
though these mice appeared to recover
somewhat after tumour resection, only
2 of the 5 tested demonstrated significant
tumour specific immunity by the colony
inhibition test.
DISCUSSION
The experiments reported here were
designed to encompass a number of
parameters in the relationship between
specific immunity and tumour growth.
Previously reported attempts to use tu-
mour cell extracts, or inactivated tumour
cells to immunize animals against chal-
lenge with viable tumour cells, have been
only marginally effective. One possible
LPS ± s.e.
mean
9-34±1-6
7-4±1-3
9-2±2-9
0-74±0-333
1-70±0-30
>0- 3
>0-3
<0-001
<0-01
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explanation for this lack of success is
that such immunization gives rise to
blocking or enhancing antibodies. The
experiments reported here would not
support this possibility, in that modified
and unmodified tumour extracts were
both equally ineffective in protecting
against tumour cell challenge. Since the
acetoacetylated extract should not stimu-
late the production of circulating anti-
bodies capable of reacting with native
tumour associated antigens, it is unlikely
that enhancing antibodies wereresponsible
for the observed results. Animals im-
munized with either modified or un-
modified extracts demonstrated cell medi-
ated immunity to tumour cells, as meas-
ured by colony inhibition, and yet were
unable to resist challenge with either 104
or 105 tumour cells. There is no ready
explanation for these obs3rvations, since
animals not developing tumour recurrence
after resection of small tumours demon-
strated similar levels of cell mediated
immunity, as measured by colony in-
hibition but were routinely resistant to
challenge with 105 tumour cells.
It is interesting to note that recent
observations byBaldwin, Price and Robins
(1973) implicate tumour associated anti-
gens and/or antigen-antibody complexes
in blocking cell mediated tumour immu-
nity. These observations are not incom-
patible with the results discussed above.
The efficiency of either nonspecific
immunostimulation with B.C.G. or specific
immunotherapy with modified and un-
modified tumour extracts in preventing
tumour recurrence after resection was
investigated. A number of clear observa-
tions were made. Significant reductions
in the frequency of tumour recurrence
in mice with tumours of between 075
and 1-0 g were obtained with immuno-
therapy utilizing a combination of B.C.G.
and either modified or unmodified tumour
extract. In protocols utilizing only one
form of immunostimulation, the modified
tumour extract was more efficient than
either the unmodified extract or B.C.G.
in preventing tumour recurrence (P< 0.2)
but none of these test groups were
significantly different from control ani-
mals. Animals in this experimental group
demonstrated specific tumour immunity
at the time of surgery and 5 days there-
after, and their spleen cells demonstrated
a normal mitogen response to ConA
and LPS.
Mice with large tumours (about 2-5 g)
responded quite differently to immuno-
therapy, in that no procedure was effective
in significantly reducing the frequency
of tumour recurrence. However, all im-
munotherapy treatments significantly pro-
longed the life of the tumour bearing
animals. These animals at the time of
surgery demonstrated essentially no tu-
mour specific immunity, and their mitogen
responses were minimal (Table IV). Five
days after surgery, there was apparently
some recovery of immunological status
in these animals although mitogen re-
sponses were still significantly lower than
untreated controls and significant tumour
specific immunity was noted in only 2
of the 5 animals so tested.
It would appear that the immuno-
logical status of the animal at the time
of tumour resection is a primary factor
in determining whether immunotherapy
will be effective in preventing tumour
recurrence. It would also appear that
while tumour extracts are not effective
in primary immunization of animals
against tumour cell challenge, they are
effective, under appropriate conditions,
as immunotherapeutic agents in prevent-
ing tumour recurrence. The reasons for
this latter observation are not clear at
this time and require further research.
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